LLMs are strong at reasoning over unstructured text. But in biology, that reasoning is hard to verify.
In our new preprint, we propose a framework for generating structured, falsifiable biological hypotheses from perturbation data.
https://t.co/cMU5jOseoa
@yunhuijang_@LuZhu66@FawkesJake@AlisandraDenton@dom_beaini@ENoutahi
We're excited to announce that MarS-FM has been accepted at ICLR!
We propose a new class of generative models that learn to sample state transitions of biomolecular systems, reproducing the statistics of Molecular Dynamics (MD) with drastic speedups.
https://t.co/mfGm6Kb4bx
News! @airstreet has raised $232,323,232 for Fund III to back AI-first companies from the earliest stages in the US and Europe.
Now the largest solo GP venture firm in Europe.
Our third epoch begins today. Join us!
🎉 It’s a clean sweep! This past weekend at @NeurIPSConf, the world's most prestigious #ML conference, papers from @valence_ai & Recursion won first, second and third place awards at the Foundation Models for Science workshop. The winning papers offer breakthroughs in leveraging ML to better model the intersection of biology & chemistry in order to improve & scale AI drug discovery. The winning papers: 🧵
News! @modal_labs is supporting @RAAIS fellowships with $10,000 credits on their platform, alongside the $5,000 GPU credits from @LambdaAPI.
Working on AI-first, open source research outside big institutions?
Apply at airstreet(dot)com/fellowships
In biology, unpaired data is the norm as experiments are often destructive. This limits our ability to build powerful multimodal models for drug discovery.
To fuel a multimodal future in TechBio, we propose a simple algorithm for matching. 🧵
https://t.co/kz1YIkWXvD
Announcing the 1st #neuroscience phenomap – “Neuromap” – optioned under our collaboration with @Roche and @Genentech for $30m. To build it, we produced over 1 trillion hiPSC-derived #neuronal cells – one of the largest such datasets – & scaled new genetic perturbation techniques. We’re combining this w/ Genentech’s #transcriptomics data to rapidly accelerate discovery of new treatments. @RecursionChris: “We look forward to initiating new programs and building more maps on the forefront of the field with our colleagues at Roche and Genentech.”
Huge day for Recursion and for neuroscience - so proud of our team for doing so many world firsts to achieve this and so excited to be working with the exceptional teams at Roche and Genentech to make great strides towards new neuro targets!
In June, we hosted the molecular machine learning conference @Mila_Quebec
With 180+ attendees and 45+ posters, it was amazing to see the progress in ML research for drug discovery.
Thank you everyone for a great conference! See you at the next MoML 👋 https://t.co/ujg4wnhv8q
Today, at the ICML workshops, @TOSSOUPrudencio shared some details on our QM data generation efforts and @folinoid discussed the latest on GFlowNets.
Come chat with us and learn more about our open roles in London. We're hiring! https://t.co/VbFCoBVtgM
As someone who has spent a lot of time writing, talking, and complaining about the sad state of benchmarks in our field, I'm incredibly excited by the Polaris platform. This effort will enable the community to easily share datasets and best practices for ML model validation.
Benchmarking is hard...but it doesn't have to be! Excited to see @Polaris_HQ launched at #ICML2024 today, w support from an awesome steering committee of industry leaders, to help up-level our collective research community. Excited to get everyone's feedback on this one :)
1/ 🚀Today, we’re excited to launch Polaris! 🚀
Polaris is a platform where the ML community working on drug discovery problems can easily share and access datasets and benchmarks.
Get started with just a few lines of code: https://t.co/6QNwad5uob
The @valence_ai team will be in Vienna for ICML next week. Join us and other TechBio friends at the @Polaris_HQ launch party on Thurs night to learn more :)
Today's benchmarking landscape for ML in drug discovery is complicated. We want to help the community develop methods that matter!🌟
Join us for our launch party at ICML on July 25th to learn more: https://t.co/FKq7Wq2T9j
“I’m a shareholder, Recursion is the largest investment we’ve ever made .. outside of our own company” - Jensen Huang at (standing room only) @RecursionPharma 2024 Download Day
Last week our Deputy Mayor for Business and Chair of @londonpartners@howarddawber along with our North American team was honoured to attend the opening of @RecursionPharma new office in #London at Pancras Square, King’s Cross 👏.
The site will provide Recursion and @valence_ai, the company’s AI research engine, access to world-class talent across Europe’s rapidly growing TechBio sector, and embed Recursion in a thriving innovation ecosystem of leading technology and life science companies 🧬.
We look forward to seeing what’s next for Recursion and welcome them to the London ecosystem 👐!
Sneak peek of the footage we got for the ML4DD summer school 👀
Today was the last day of the summer school. With 150+ participants, it was exciting to see the growing interest of TechBio. Thank you to all of our speakers!
See you tomorrow @Mila_Quebec for MoML 2024 👋